论文部分内容阅读
目的研究国产卡铂（ＣＢＰ）的临床药代动力学与药效学。方法１２例肿瘤病人静滴ＣＢＰ４００ｍｇ。用反相高效液相色谱法测定血清ＣＢＰ浓度；按１９７８年常州会议制定的标准作疗效评定。结果静滴结束时的平均血药浓度（Ｃｏ）为５４．７９±１１８１ｍｇ．ｍｌ－１，消除半衰期（Ｔ１／２β）为１４３．１２±４９．４１ｍｉｎ。有４例部分缓解（ＰＲ），８例稳定（ＮＣ）或进展（ＰＤ）。有效组（ＰＲ）和无效组（ＮＣ＋ＰＤ）的Ｃｏ分别为６１．０３±９．２８和５２．１４±１２．７７ｍｇ．Ｌ－１，Ｔ１／２β分别为１９１．２７±２６．９２和１１９．００±３５．３１ｍｉｎ（Ｐ＜０．０１）。在２～１０ｈ内，有效组血清ＣＢＰ浓度高于无效组（Ｐ＜０．０５）。结论肿瘤病人静滴ＣＢＰ的血药浓度存在明显个体差异。疗效与血药浓度和消除快慢有关
Objective To study the clinical pharmacokinetics and pharmacodynamics of domestic carboplatin (CBP). Methods 12 patients with tumor patients intravenous infusion of CBP400mg. The concentration of serum CBP was determined by RP-HPLC. The therapeutic effect was evaluated according to the standard set by Changzhou Conference in 1978. Results The mean blood concentration (Co) at the end of intravenous infusion was 54.79 ± 1181 mg. ml-1, the elimination half-life (T1 / 2β) was 143.12 ± 49.41min. There were 4 patients with partial response (PR), 8 patients with stable (NC) or progression (PD). The Co of the valid group (PR) and the ineffective group (NC + PD) were 61.03 ± 9.28 and 52.14 ± 12.77 mg, respectively. L-1 and T1 / 2β were 191.27 ± 26.92 and 119.00 ± 35.31min respectively (P <0.01). Within 2 ~ 10h, the effective serum CBP concentration was higher than the invalid group (P <0.05). Conclusion There is a clear individual difference in plasma concentration of CBP in patients with tumor. Efficacy and blood concentration and the elimination of speed related